Oxaliplatin: a review of preclinical and clinical studies.

[1]  S. Mcdougall,et al.  Biotransformation and pharmacokinetic analysis of oxaliplatin in patients with advanced gastrointestinal cancer , 1998 .

[2]  J. Armand,et al.  Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC) , 1998 .

[3]  E. Raymond,et al.  Activity of oxaliplatin against human tumor colony-forming units. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  E. Raymond,et al.  Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers , 1997, Anti-cancer drugs.

[5]  F. Lévi,et al.  Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer , 1997, The Lancet.

[6]  O. Bouché,et al.  Addition of oxaliplatin (Eloxatine®, LOHP) to the same leucovorin (LV) and 5 fluorouracil (5FU) bimonthly regimens after progression in patients (pts) with metastatic colorectal cancer (MCRC): Preliminary report , 1997 .

[7]  P. Soulié,et al.  Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. , 1997, European journal of cancer.

[8]  J. Robert,et al.  Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  K. Kinzler,et al.  Genetic instability in colorectal cancers , 1997, Nature.

[10]  P. Karran,et al.  Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. , 1997, Nucleic acids research.

[11]  D. R. Duckett,et al.  Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems , 1997, Molecular and cellular biology.

[12]  C. Tournigand,et al.  Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.

[13]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[14]  K. Paull,et al.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. , 1996, Biochemical pharmacology.

[15]  P. Chollet,et al.  Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  R. Rietbroek,et al.  In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. , 1996, Carcinogenesis.

[17]  S. Aebi,et al.  The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.

[18]  F. Lévi,et al.  Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Fargeot,et al.  Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. , 1996, European journal of cancer. Part B, Oral oncology.

[20]  J. Essigmann,et al.  The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. , 1996, Chemistry & biology.

[21]  C. Boland,et al.  Loss of DNA mismatch repair in acquired resistance to cisplatin. , 1996, Cancer research.

[22]  C. Boland,et al.  Transcription-Coupled Repair Deficiency and Mutations in Human Mismatch Repair Genes , 1996, Science.

[23]  R. Brown,et al.  Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. , 1996, Cancer research.

[24]  T. Kunkel,et al.  Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. , 1995, Cancer research.

[25]  R. Perez,et al.  Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. , 1995, Cancer letters.

[26]  C. Tournigand,et al.  716 Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 H infusion in pretreated metastatic colorectal cancer (CRC) , 1995 .

[27]  F. Lévi,et al.  124 Addition of oxaliplatin (L-OHP®) to chronomodulated (CM) 5-fluorouracil (5-FU) and folinic acid (FA) for reversal of acquired chemoresistance in patients with advance colorectal cancer (ACC) , 1995 .

[28]  S. Brienza,et al.  933 Oxaliplatin (L-OHP®): Global safety in 682 patients (PTS) , 1995 .

[29]  N. Saijo,et al.  Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. , 1995, Anticancer research.

[30]  F. Lévi,et al.  Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. , 1994, Journal of the National Cancer Institute.

[31]  P. Soulié,et al.  Feasibility of high-dose platinum delivery with combined carboplatin and oxaliplatin. , 1994, Journal of the National Cancer Institute.

[32]  W. Kaufmann,et al.  Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. , 1994, Cancer research.

[33]  L. Pendyala,et al.  In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. , 1993, Cancer research.

[34]  A. Khokhar,et al.  Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands. , 1993, Cancer research.

[35]  W. Thilly,et al.  An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Aquilina,et al.  Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage , 1993, Nature.

[37]  A. Khokhar,et al.  Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. , 1993, Anti-cancer drugs.

[38]  S. Chaney,et al.  Role of carrier ligand in platinum resistance of human carcinoma cell lines. , 1993, Cancer research.

[39]  L. Kèlland,et al.  Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. , 1992, British Journal of Cancer.

[40]  M. Markman,et al.  Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Le Bouil,et al.  Evaluation of inductively coupled mass spectrometry for the determination of platinum in plasma. , 1992, Biological mass spectrometry.

[42]  A. Reinberg,et al.  A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer , 1992, Cancer.

[43]  V. Brabec,et al.  Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. , 1992, Nucleic acids research.

[44]  W. Kaufmann,et al.  Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. , 1991, Carcinogenesis.

[45]  M. Broggini,et al.  Cis dichlorodiammine platinum induced DNA interstrand cross-links in primary cultures of human ovarian cancer. , 1991, British Journal of Cancer.

[46]  R. Ozols,et al.  Comparative cytotoxicity of CI‐973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines , 1991, International Journal of Cancer.

[47]  B. Teicher,et al.  Characteristics of five human tumor cell lines and sublines resistant to cis‐diamminedichloroplatinum(II) , 1991, International journal of cancer.

[48]  S. Lippard,et al.  195Pt NMR Kinetic and Mechanistic Studies of cis- and trans-Diamminedichloroplatinum(II) Binding to DNA. , 1990 .

[49]  S. Chaney,et al.  Role of carrier ligand in platinum resistance in L1210 cells. , 1990, Cancer research.

[50]  Christopher A. Lepre,et al.  Platinum-195 NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA , 1990 .

[51]  F. Lévi,et al.  Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. , 1990, Journal of the National Cancer Institute.

[52]  S. Chaney,et al.  Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. , 1990, Biochemistry.

[53]  L. Kèlland,et al.  Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. , 1989, British Journal of Cancer.

[54]  D. Hamer,et al.  Overexpression of metallothionein confers resistance to anticancer drugs. , 1988, Science.

[55]  S. Wyrick,et al.  Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. , 1988, Cancer research.

[56]  A. de Gramont,et al.  High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. , 1988, European journal of cancer & clinical oncology.

[57]  S. Wyrick,et al.  Displacement of the bidentate malonate ligand from (d,l-trans-1,2-diaminocyclohexane)malonatoplatinum(II) by physiologically important compounds in vitro. , 1988, Biochemical pharmacology.

[58]  A. Eastman,et al.  Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. , 1987, Cancer research.

[59]  W. Schaller,et al.  Kinetic investigation of the DNA platination reaction: evidence for a transient adduct between deoxyribonucleic acid and cis-platinum(II). , 1987, Biochemistry.

[60]  R C Young,et al.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. , 1987, Cancer research.

[61]  V. Narayanan,et al.  Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane. , 1986, Cancer treatment reports.

[62]  A. Eastman.  Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. , 1986, Biochemistry.

[63]  D. Lydall,et al.  Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. , 1986, Cancer research.

[64]  A. Mazard,et al.  Kinetics of the reaction of cis-platinum compounds with DNA in vitro. , 1985, Biochemical and biophysical research communications.

[65]  G. Mathé,et al.  Antitumor activity of l-OHP in mice. , 1985, Cancer letters.

[66]  P. Lohman,et al.  Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. , 1985, Biochemistry.

[67]  Kenji Inagaki,et al.  The crystal structures and absolute configurations of the anti-tumor complexes Pt(oxalato)(1R,2R-cyclohexanediamine) and Pt(malonato)(1R,2R-cyclohexanediamine) , 1984 .

[68]  J. Miller,et al.  Mutagenicity, tumorigenicity, and electrophilic reactivity of the stereoisomeric platinum(II) complexes of 1,2-diaminocyclohexane. , 1981, Cancer research.

[69]  T. Tashiro,et al.  Relation of conformation to antitumor activity of platinum(II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine isomers against leukemia P388. , 1981, Journal of medicinal chemistry.

[70]  P. Pilon,et al.  Tris[cis-dichloro(1,2-diaminocyclohexane)platinum(II)] hydrate and cis-dibromo(1,2-diaminocyclohexane)platinum(II) , 1981 .

[71]  T. Tashiro,et al.  Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers. , 1980, Gan.

[72]  J. Hoeschele,et al.  Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA. , 1980, Chemico-biological interactions.

[73]  J. Burchenal,et al.  Rationale for development of platinum analogs. , 1979, Cancer treatment reports.

[74]  K. Kohn,et al.  DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. , 1979, Cancer research.

[75]  J. Burchenal,et al.  Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives , 1978 .

[76]  K. Inagaki,et al.  Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form. , 1978, Journal of medicinal chemistry.

[77]  T. Tashiro,et al.  Antitumor activity of water-soluble platinum(II) complexes of 1,2-cyclohexanediamine isomers. , 1978, Gan.

[78]  L. M. Atkins,et al.  Synergistic action of high‐dose hydroxyurea when used with cyglophosphamide and certain new organoplatinum complexes in treatment of advanced L1210 leukemia , 1978, Cancer.

[79]  K. Inagaki,et al.  Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes. , 1976, Gan.

[80]  L. M. Atkins,et al.  Antileukemic properties of dichloro(1,2-diaminocyclohexane)platinum(II). , 1974, Research communications in chemical pathology and pharmacology.

[81]  T. A. Connors,et al.  New platinum complexes with anti-tumour activity. , 1972, Chemico-biological interactions.

[82]  R. Labianca,et al.  Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  M. Ychou,et al.  Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  城戸 祐一郎.  Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum(IV) complexes mediated by axial and equatorial ligands , 1995 .

[85]  P. Fumoleau,et al.  Preliminary phase II trial of oxaliplatin (L-OHP) in malignant astrocytomas , 1993 .

[86]  M. Palma,et al.  Oxaliplatin (L-OHP®): A new platinum analog: Active in refractory/relapsed intermediate and low crade non-Hodgkin lymphoma (NHL): A phase I–II study , 1993 .

[87]  L. Biganzoli,et al.  Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines. , 1993, European journal of cancer.

[88]  S. Iacobelli,et al.  Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. , 1993, European journal of cancer.

[89]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  A. Eastman,et al.  The role of DNA repair in resistance of L1210 cells to isomeric 1,2-diaminocyclohexaneplatinum complexes and ultraviolet irradiation. , 1991, Mutation research.

[91]  S. Howell.  Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy , 1991, Springer US.

[92]  S. Howell,et al.  Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. , 1990, Cancer communications.

[93]  T. Tashiro,et al.  Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[94]  J. Misset,et al.  Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[95]  A. Eastman,et al.  Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. , 1989, Chemico-biological interactions.

[96]  A. Kraker,et al.  Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. , 1988, Cancer research.

[97]  J. Misset,et al.  A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). , 1986, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[98]  J. Hoeschele,et al.  Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum (II) complexes , 1973 .